To assess the engraftment of hESC-derived photoreceptors and their ability to restore vision in early and advanced stages of Retinitis Pigmentosa.

评估 hESC 来源的光感受器的植入及其在色素性视网膜炎早期和晚期恢复视力的能力。

基本信息

  • 批准号:
    MR/X001687/1
  • 负责人:
  • 金额:
    $ 136.17万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2023
  • 资助国家:
    英国
  • 起止时间:
    2023 至 无数据
  • 项目状态:
    未结题

项目摘要

The retina is an extension of the central nervous system that lines the back of the eye, transmitting information from our visual world to the brain via the optic nerve. One of the important roles of the retina is to convert light into electrical signals, a process called phototransduction. These electrical signals are subsequently transmitted across retinal networks, eventually generating impulses in the optic nerve that connects the eye to the brain. Once these impulses reach central visual brain areas, they lead to visual perception. The cells responsible for phototransduction are the photoreceptors, the rods (responsible for vision in dim light conditions) and the cones (responsible for colour vision in bright light conditions and for our ability to see sharp details). One of the main causes of blindness is rod/cone malfunction, often due to genetic mutations (hereditary photoreceptor dystrophies). When these cells do not function properly, they gradually degenerate, leading to partial or total and irreversible blindness. There are currently no available preventative treatments or new therapeutic interventions that can successfully hinder disease progression or offer long-term promising outlook for patients suffering from these devastating conditions. Retinitis pigmentosa (RP) is a common form of hereditary photoreceptor dystrophy associated with progressive rod degeneration of the mid-peripheral retina, leading to night blindness and loss of visual acuity. At later stages of the disease, cones degenerate as well, resulting in complete blindness at final disease stages. Therefore, there is a pressing need to develop novel approaches either for photoreceptor replacement or for reactivation of dysfunctional surviving photoreceptor by gene therapy (if performed at early stages of the disease).In our group, we develop artificial retinas (organoids) derived from human pluripotent stem cells (hPSCs). We isolate photoreceptors from these organoids and inject them in retinas with photoreceptor dystrophies, with the goal to achieve integration of these new healthy photoreceptors into the host retina, eventually restoring visual function. We have successfully achieved these goals using a cone-enriched population of photoreceptor precursors in a mouse model of RP, resulting in partial restoration of visual function assessed by behavioural and electrophysiological testing. However, given the prevalence of rod degeneration in RP, our hypothesis is that transplantation of hPSCs-derived rods at early stages may lead to improved rod integration and function, while also protecting cones from degenerating at later stages. In addition, we suggest that a combination of rod and cone transplantation may achieve optimal results at more advanced stages of retinal degeneration.Here we propose to test this hypothesis in a mouse model of RP. We will develop new hPSC lines, which will enable enrichment of cone and rod precursors, each one carrying a genetically encoded fluorescent marker of a different colour for easier identification once engrafted in the host retina. In one set of experiments, we will inject rods alone at early degeneration stages, with the goal of improving their integration into the host retina and protecting cones from later degeneration. In another set of experiments, we will inject a mixed population of rod and cone precursors at later stages of degeneration, to see whether this approach protects cones from ensuing degeneration. Using all the tools we have developed to generate homogenous populations of cone and rod precursors from hPSCs, perform successful cell transplantation and assess vision restoration using behavioural and electrophysiological approaches, this project will provide fundamental knowledge to establish the optimal conditions necessary for successful large-scale engraftment of stem cell-derived healthy photoreceptors to restore sight in devastating photoreceptor dystrophies.
视网膜是中枢神经系统的延伸,位于眼睛后部,通过视神经将信息从我们的视觉世界传输到大脑。视网膜的重要作用之一是将光转换为电信号,这一过程称为光转导。这些电信号随后通过视网膜网络传输,最终在连接眼睛和大脑的视神经中产生脉冲。一旦这些冲动到达中枢视觉大脑区域,就会产生视觉感知。负责光转导的细胞是光感受器、视杆细胞(负责弱光条件下的视觉)和视锥细胞(负责强光条件下的色觉以及我们看到清晰细节的能力)。失明的主要原因之一是视杆细胞/视锥细胞功能障碍,通常是由于基因突变(遗传性感光细胞营养不良)造成的。当这些细胞不能正常工作时,它们会逐渐退化,导致部分或全部和不可逆转的失明。目前尚无可用的预防性治疗或新的治疗干预措施可以成功阻止疾病进展或为患有这些破坏性疾病的患者提供长期有希望的前景。色素性视网膜炎 (RP) 是遗传性感光细胞营养不良的一种常见形式,与中周边视网膜进行性杆状变性相关,导致夜盲症和视力丧失。在疾病的后期阶段,视锥细胞也会退化,导致疾病最终阶段完全失明。因此,迫切需要开发新的方法来替代光感受器或通过基因疗法重新激活功能失调的存活光感受器(如果在疾病的早期阶段进行)。在我们的小组中,我们开发了源自​​人类的人造视网膜(类器官)多能干细胞(hPSC)。我们从这些类器官中分离出光感受器,并将它们注射到患有光感受器营养不良的视网膜中,目标是将这些新的健康光感受器整合到宿主视网膜中,最终恢复视觉功能。我们在 RP 小鼠模型中使用富含视锥细胞的光感受器前体群体成功实现了这些目标,从而通过行为和电生理测试评估视觉功能的部分恢复。然而,考虑到 RP 中视杆细胞退化的普遍性,我们的假设是,在早期阶段移植 hPSC 衍生的视杆细胞可能会改善视杆细胞的整合和功能,同时还能保护视锥细胞在后期免受退化。此外,我们认为视杆细胞和视锥细胞移植的结合可能会在视网膜变性的更晚期阶段获得最佳结果。在这里,我们建议在 RP 小鼠模型中检验这一假设。我们将开发新的 hPSC 系,这将能够富集视锥细胞和视杆细胞前体,每个细胞都携带不同颜色的基因编码荧光标记,以便在植入宿主视网膜后更容易识别。在一组实验中,我们将在早期退化阶段单独注射视杆细胞,目的是改善它们与宿主视网膜的整合并保护视锥细胞免受后期退化。在另一组实验中,我们将在退化的后期注射视杆细胞和视锥细胞前体的混合群体,以观察这种方法是否可以保护视锥细胞免于随后的退化。利用我们开发的所有工具,从 hPSC 中产生同质的视锥细胞和视杆细胞前体群体,进行成功的细胞移植,并使用行为和电生理学方法评估视力恢复情况,该项目将提供基础知识,以建立成功大规模生产所需的最佳条件。植入干细胞衍生的健康光感受器,以在破坏性光感受器营养不良中恢复视力。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Light-responsive microRNA molecules in human retinal organoids are differentially regulated by distinct wavelengths of light
人视网膜类器官中的光响应 microRNA 分子受到不同波长的光的差异调节
  • DOI:
    http://dx.10.1016/j.isci.2023.107237
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    5.8
  • 作者:
    Celiker C
  • 通讯作者:
    Celiker C
Spatiotemporal single cell analyses reveal a transient population of retinal progenitor cells in the ciliary margin of developing human retina
时空单细胞分析揭示了发育中的人类视网膜的睫状缘中存在短暂的视网膜祖细胞群
  • DOI:
  • 发表时间:
    1970-01-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
    M. Lako;B. Dorgau;Agata Rozanska;Darin Zerti;Moira Crossier;Jonathan Coxhead;David FitzPatrick;R. Queen
  • 通讯作者:
    R. Queen
Editorial: Methods and advances in induced pluripotent stem cells-ophthalmology
社论:诱导多能干细胞眼科的方法和进展
Deciphering the spatio-temporal transcriptional and chromatin accessibility of human retinal organoid development at the single cell level
在单细胞水平上破译人类视网膜类器官发育的时空转录和染色质可及性
  • DOI:
    http://dx.10.1101/2023.07.19.549507
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Dorgau B
  • 通讯作者:
    Dorgau B
Incorporating microglia-like cells in human induced pluripotent stem cell-derived retinal organoids.
将小胶质细胞样细胞纳入人类诱导多能干细胞衍生的视网膜类器官中。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Majlinda Lako其他文献

Majlinda Lako的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Majlinda Lako', 18)}}的其他基金

Off-the-shelf hypoimmunogenic photoreceptors for treatment of blinding retinal disease
现成的低免疫原性光感受器用于治疗致盲性视网膜疾病
  • 批准号:
    EP/Y031016/1
  • 财政年份:
    2024
  • 资助金额:
    $ 136.17万
  • 项目类别:
    Research Grant
Assessing SARS-CoV-2 entry, replication and prevention in a primary human conjunctival cell model and organ cultured cornea/conjunctiva.
评估原代人类结膜细胞模型和器官培养角膜/结膜中 SARS-CoV-2 的进入、复制和预防。
  • 批准号:
    BB/V01126X/1
  • 财政年份:
    2020
  • 资助金额:
    $ 136.17万
  • 项目类别:
    Research Grant
Elucidating splicing factor function and retinal splicing programmes: developing new therapeutic strategies for splicing factor retinitis pigmentosa
阐明剪接因子功能和视网膜剪接方案:开发剪接因子色素性视网膜炎的新治疗策略
  • 批准号:
    MR/T017503/1
  • 财政年份:
    2020
  • 资助金额:
    $ 136.17万
  • 项目类别:
    Research Grant
A single cell sequencing approach to determine the heterogeneity, dynamics and cell fate decisions of retinal progenitor cells in vivo and in vitro
一种单细胞测序方法,用于确定体内和体外视网膜祖细胞的异质性、动态和细胞命运决定
  • 批准号:
    BB/T004460/1
  • 财政年份:
    2020
  • 资助金额:
    $ 136.17万
  • 项目类别:
    Research Grant
Understanding the molecular and cellular complexity of human cornea through single cell analyses
通过单细胞分析了解人类角膜的分子和细胞复杂性
  • 批准号:
    MR/S035826/1
  • 财政年份:
    2018
  • 资助金额:
    $ 136.17万
  • 项目类别:
    Research Grant
Using zinc finger nuclease technology to generate reporter-labelled human pluripotent stem cells as a tool to optimize photoreceptor transplantation
使用锌指核酸酶技术生成报告基因标记的人类多能干细胞作为优化光感受器移植的工具
  • 批准号:
    BB/I02333X/1
  • 财政年份:
    2011
  • 资助金额:
    $ 136.17万
  • 项目类别:
    Research Grant
A state of the art multiparametric flow cytometry analysis system for multidisciplinary stem cell research
用于多学科干细胞研究的最先进的多参数流式细胞术分析系统
  • 批准号:
    BB/E012841/1
  • 财政年份:
    2007
  • 资助金额:
    $ 136.17万
  • 项目类别:
    Research Grant

相似国自然基金

植入式感存算一体脑机接口片上系统研究
  • 批准号:
    62371329
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
超声触发阳离子型一氧化碳释放载体的构筑及其对植入物感染治疗应用研究
  • 批准号:
    22305239
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
INSL4在胎盘植入性疾病滋养层细胞分化中的作用及机制研究
  • 批准号:
    82371685
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
载氢异质结修饰钛植入体修复感染性骨缺损研究
  • 批准号:
    82372375
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目

相似海外基金

リンドウのゲノムに挿入された新種カリモウイルスと植物との相互作用解析
插入龙胆基因组的新型卡利莫病毒与植物的相互作用分析
  • 批准号:
    24K08905
  • 财政年份:
    2024
  • 资助金额:
    $ 136.17万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Functional Regeneration and Engraftment of Cardiomyocytes Derived from Human Induced Pluripotent Stem Cells by Brief Cycles of Transient Reprogramming
通过短暂的瞬时重编程周期改善人诱导多能干细胞来源的心肌细胞的功能再生和植入
  • 批准号:
    24K11267
  • 财政年份:
    2024
  • 资助金额:
    $ 136.17万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
同種造血幹細胞移植後合併症の動的重症度評価システムの開発と早期介入の検証
异基因造血干细胞移植后并发症动态严重程度评估系统的建立及早期干预的验证
  • 批准号:
    24K10601
  • 财政年份:
    2024
  • 资助金额:
    $ 136.17万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
針葉樹人工林内に一斉入植したミズナラ集団の次世代の遺伝的評価
对针叶人工林中定居的栎树种群下一代的遗传评估
  • 批准号:
    24K09008
  • 财政年份:
    2024
  • 资助金额:
    $ 136.17万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Optimization of CAR-Bacteria for Oral Cancer
口腔癌 CAR 细菌的优化
  • 批准号:
    10648292
  • 财政年份:
    2023
  • 资助金额:
    $ 136.17万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了